Jan van Riggelen
Overview
Explore the profile of Jan van Riggelen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
1222
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu M, Klement J, Langan C, van Riggelen J, Liu K
Cell Immunol
. 2021 Jun;
366:104397.
PMID: 34157461
T lymphoma cells may constitutively express PD-1 and PD-L1. The relative role of PD-1 and PD-L1 in T lymphoma is incompletely understood. We report here that PD-1 PDL-1 human T...
2.
Alptekin A, Ye B, Yu Y, Poole C, van Riggelen J, Zha Y, et al.
Oncogene
. 2019 Aug;
38(50):7504-7520.
PMID: 31444411
Genomic amplification of the oncogene MYCN is a major driver in the development of high-risk neuroblastoma, a pediatric cancer with poor prognosis. Given the challenge in targeting MYCN directly for...
3.
Poole C, Lodh A, Choi J, van Riggelen J
Epigenetics Chromatin
. 2019 Jul;
12(1):41.
PMID: 31266538
Background: While aberrant DNA methylation is a characteristic feature of tumor cells, our knowledge of how these DNA methylation patterns are established and maintained is limited. DNA methyltransferases and ten-eleven...
4.
Cai Y, Zhu G, Liu S, Pan Z, Quintero M, Poole C, et al.
Cell Discov
. 2019 Feb;
5:7.
PMID: 30701081
Intestinal exocrine secretory cells, including Paneth and goblet cells, have a pivotal role in intestinal barrier function and mucosal immunity. Dysfunction of these cells may lead to the pathogenesis of...
5.
Poole C, Zheng W, Lee H, Young D, Lodh A, Chadli A, et al.
Cancers (Basel)
. 2018 Nov;
10(11).
PMID: 30453475
Overexpression of the MYC oncogene is a key feature of many human malignancies including Burkitt lymphoma. While MYC is widely regarded to be a promising therapeutic target, a clinically effective...
6.
Hu T, Wu Q, Chong Y, Qin H, Poole C, van Riggelen J, et al.
Leukemia
. 2018 May;
32(11):2363-2373.
PMID: 29720732
Oncogenic transformation of hematopoietic stem cells by chimeric fusion kinases causing constitutive activation of FGFR1 leads to a stem cell leukemia/lymphoma (SCLL) syndrome, accompanied by widespread dysregulation of gene activity....
7.
Poole C, Zheng W, Lodh A, Yevtodiyenko A, Liefwalker D, Li H, et al.
Oncotarget
. 2017 Nov;
8(44):76898-76920.
PMID: 29100357
Aberrant DNA methylation is a hallmark of cancer. However, our understanding of how tumor cell-specific DNA methylation patterns are established and maintained is limited. Here, we report that in T-cell...
8.
Poole C, van Riggelen J
Genes (Basel)
. 2017 May;
8(5).
PMID: 28505071
Overexpression of is a hallmark of many human cancers. The oncogene has long been thought to execute its neoplastic functions by acting as a classic transcription factor, deregulating the expression...
9.
Yetil A, Anchang B, Gouw A, Adam S, Zabuawala T, Parameswaran R, et al.
Oncotarget
. 2015 Mar;
6(6):3563-77.
PMID: 25784651
MYC-induced T-ALL exhibit oncogene addiction. Addiction to MYC is a consequence of both cell-autonomous mechanisms, such as proliferative arrest, cellular senescence, and apoptosis, as well as non-cell autonomous mechanisms, such...
10.
Wu A, Kawahara T, Rapicavoli N, van Riggelen J, Shroff E, Xu L, et al.
Lab Chip
. 2012 May;
12(12):2190-8.
PMID: 22566096
Chromatin immunoprecipitation (ChIP) is an assay for interrogating protein-DNA interactions that is increasingly being used for drug target discovery and screening applications. Currently the complexity of the protocol and the...